New York Academy of Medicine
A pioneer in the health care investment field, Dr. Mitchell Blutt serves as chief executive officer of Consonance Capital in New York City. With more than three decades of experience in the field, he oversees the company’s private and public equity investment divisions. Outside of his work, Dr. Mitchell Blutt maintains membership in the New York Academy of Medicine (NYAM).
According to a recent report by NYAM, allocating more money to purchasing fresh food grown in New York State could not only be an economic boon for the state’s farmers, but also provides an opportunity to improve the health of residents in a number of public settings. Childcare facilities, adult care centers, food pantries, and other public-facing entities often rely on tax dollars to help fund a portion of their operations. By spending that money on fresh, New York-grown food, the agencies could help the people who depend on their services realize a decreased risk of developing chronic diseases.
The state spends nearly $1 billion each year on food for these institutions. Only 10 percent of that amount, however, goes to purchasing foods that are locally grown in New York. In the report, NYAM recommends that figure be upped to 25 percent, which not only will bring more fresh-grown food to New Yorkers, but will also help spur the state’s farming industries through local investment.
Weill Cornell Dean’s Council
After earning a doctor of medicine from the University of Pennsylvania School of Medicine and an MBA from Wharton, Mitchell Blutt went on to launch the health care investment business at JPMorgan Partners and subsequently founded Consonance Capital. In addition to his role as an instructor at Weill Cornell Medical College in New York City, Mitchell Blutt serves on its Dean’s Council.
The Weill Cornell Medical College Dean’s Council exists to help advance research, patient care, and instruction in the Weill Cornell community through the efforts of its members. Dedicated to philanthropy and major giving to the college, Dean’s Council members build relationships with Weill Cornell’s best physicians and faculty while learning more about how their contributions advance positive change in the medical field.
Dean’s Council donors are in turn recognized through a variety of societies and appellation giving opportunities, such as endowments for student scholarships and research. For instance, The Lewis Atterbury Stimson Society holds a recognition luncheon for its donors every spring. Those that contribute to the Council also receive a newsletter with information about how the money is being spent.
Weill Cornell Medical College
Dedicated to the advancement of medical science, Dr. Mitchell Blutt has promoted and supported research in both the public and private sectors. Dr. Mitchell Blutt leads as CEO of healthcare investment group Consonance Capital and serves on the Dean’s Council of Weill Cornell Medical College.
In July of 2017, researchers at Weill Cornell Medical College announced the creation of a dissolvable device that could decrease the risk of damage to internal organs during the closing phase of surgery. The device was developed largely due to the practice experiences of Dr. Jason Spector, a plastic surgeon and professor at Weill Cornell. Noting that medical science at the time offered no way of protecting the vital organs during surgical wound closure, thus leaving many patients at risk of internal damage, he consulted with biomedical engineering professor Dr. David Putnam.
Dr. Putnam reported that his graduate student, Nicole Ricapito, had developed a material that was not only strong enough to protect intestinal tissue and flexible enough to pass through a minimally-invasive surgical incision, but also capable of dissolving in the patient’s body. Drs. Putnam and Spector used this compound, made of polyethylene glycol and dihydroxyacetone (DHA), to craft a device that effectively protected mouse intestines during abdominal suturing and then rapidly dissolved in the abdominal cavity.
The researchers found that because DHA and polyethylene glycol both dissolve when exposed to water, the device would break down in less than three hours with no lasting effects. Encouraged by these results, the researchers are currently moving toward pre-clinical testing, to ensure that the technology is safe and effective enough to introduce into the commercial market.